A citation-based method for searching scientific literature

Yubao Wang, Tinghu Zhang, Nicholas Kwiatkowski, Brian J Abraham, Tong Ihn Lee, Shaozhen Xie, Haluk Yuzugullu, Thanh Von, Heyuan Li, Ziao Lin, Daniel G Stover, Elgene Lim, Zhigang C Wang, J Dirk Iglehart, Richard A Young, Nathanael S Gray, Jean J Zhao. Cell 2015
Times Cited: 255







List of co-cited articles
1069 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.
Nicholas Kwiatkowski, Tinghu Zhang, Peter B Rahl, Brian J Abraham, Jessica Reddy, Scott B Ficarro, Anahita Dastur, Arnaud Amzallag, Sridhar Ramaswamy, Bethany Tesar,[...]. Nature 2014
487
51

Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.
Camilla L Christensen, Nicholas Kwiatkowski, Brian J Abraham, Julian Carretero, Fatima Al-Shahrour, Tinghu Zhang, Edmond Chipumuro, Grit S Herter-Sprie, Esra A Akbay, Abigail Altabef,[...]. Cancer Cell 2014
277
47

CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer.
Edmond Chipumuro, Eugenio Marco, Camilla L Christensen, Nicholas Kwiatkowski, Tinghu Zhang, Clark M Hatheway, Brian J Abraham, Bandana Sharma, Caleb Yeung, Abigail Altabef,[...]. Cell 2014
366
46

Transcriptional Addiction in Cancer.
James E Bradner, Denes Hnisz, Richard A Young. Cell 2017
492
30

Super-enhancers in the control of cell identity and disease.
Denes Hnisz, Brian J Abraham, Tong Ihn Lee, Ashley Lau, Violaine Saint-André, Alla A Sigova, Heather A Hoke, Richard A Young. Cell 2013
25

Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Jakob Lovén, Heather A Hoke, Charles Y Lin, Ashley Lau, David A Orlando, Christopher R Vakoc, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2013
25

Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II.
Stéphane Larochelle, Ramon Amat, Kira Glover-Cutter, Miriam Sansó, Chao Zhang, Jasmina J Allen, Kevan M Shokat, David L Bentley, Robert P Fisher. Nat Struct Mol Biol 2012
239
25

Master transcription factors and mediator establish super-enhancers at key cell identity genes.
Warren A Whyte, David A Orlando, Denes Hnisz, Brian J Abraham, Charles Y Lin, Michael H Kagey, Peter B Rahl, Tong Ihn Lee, Richard A Young. Cell 2013
21

Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype.
Calla M Olson, Yanke Liang, Alan Leggett, Woojun D Park, Lianbo Li, Caitlin E Mills, Selma Z Elsarrag, Scott B Ficarro, Tinghu Zhang, Robert Düster,[...]. Cell Chem Biol 2019
57
36

Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Bo Li, Triona Ni Chonghaile, Yue Fan, Stephen F Madden, Rut Klinger, Aisling E O'Connor, Louise Walsh, Gillian O'Hurley, Girish Mallya Udupi, Jesuchristopher Joseph,[...]. Cancer Res 2017
53
35

Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma.
Yan-Yi Jiang, De-Chen Lin, Anand Mayakonda, Masaharu Hazawa, Ling-Wen Ding, Wen-Wen Chien, Liang Xu, Ye Chen, Jin-Fen Xiao, William Senapedis,[...]. Gut 2017
117
18

Cyclin-dependent kinases.
Marcos Malumbres. Genome Biol 2014
683
18

The history and future of targeting cyclin-dependent kinases in cancer therapy.
Uzma Asghar, Agnieszka K Witkiewicz, Nicholas C Turner, Erik S Knudsen. Nat Rev Drug Discov 2015
908
18

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
17

Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7.
Shanhu Hu, Jason J Marineau, Nisha Rajagopal, Kristin B Hamman, Yoon Jong Choi, Darby R Schmidt, Nan Ke, Liv Johannessen, Michael J Bradley, David A Orlando,[...]. Cancer Res 2019
56
30

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.
Hua Zhang, Camilla L Christensen, Ruben Dries, Matthew G Oser, Jiehui Deng, Brian Diskin, Fei Li, Yuanwang Pan, Xuzhu Zhang, Yandong Yin,[...]. Cancer Cell 2020
80
20

ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.
Hetal Patel, Manikandan Periyasamy, Georgina P Sava, Alexander Bondke, Brian W Slafer, Sebastian H B Kroll, Marion Barbazanges, Richard Starkey, Silvia Ottaviani, Alison Harrod,[...]. Mol Cancer Ther 2018
52
28

Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.
S A Greenall, Y C Lim, C B Mitchell, K S Ensbey, B W Stringer, A L Wilding, G M O'Neill, K L McDonald, D J Gough, B W Day,[...]. Oncogenesis 2017
44
34

Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
Tinghu Zhang, Nicholas Kwiatkowski, Calla M Olson, Sarah E Dixon-Clarke, Brian J Abraham, Ann K Greifenberg, Scott B Ficarro, Jonathan M Elkins, Yanke Liang, Nancy M Hannett,[...]. Nat Chem Biol 2016
158
15

THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing.
Kyle A Nilson, Jiannan Guo, Michael E Turek, John E Brogie, Elizabeth Delaney, Donal S Luse, David H Price. Mol Cell 2015
99
14

THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Ping Lu, Jing Geng, Lei Zhang, Yu Wang, Ningning Niu, Yuan Fang, Fang Liu, Juanjuan Shi, Zhi-Gang Zhang, Yong-Wei Sun,[...]. Oncogene 2019
28
50

A Phase Separation Model for Transcriptional Control.
Denes Hnisz, Krishna Shrinivas, Richard A Young, Arup K Chakraborty, Phillip A Sharp. Cell 2017
770
13

Super-Enhancer-Driven Transcriptional Dependencies in Cancer.
Satyaki Sengupta, Rani E George. Trends Cancer 2017
118
13

Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors.
Sampada Kalan, Ramon Amat, Miriam Merzel Schachter, Nicholas Kwiatkowski, Brian J Abraham, Yanke Liang, Tinghu Zhang, Calla M Olson, Stéphane Larochelle, Richard A Young,[...]. Cell Rep 2017
46
28

Preclinical Efficacy and Molecular Mechanism of Targeting CDK7-Dependent Transcriptional Addiction in Ovarian Cancer.
Zhenfeng Zhang, Huixin Peng, Xiaojie Wang, Xia Yin, Pengfei Ma, Ying Jing, Mei-Chun Cai, Jin Liu, Meiying Zhang, Shengzhe Zhang,[...]. Mol Cancer Ther 2017
42
30

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.
Marc R Mansour, Brian J Abraham, Lars Anders, Alla Berezovskaya, Alejandro Gutierrez, Adam D Durbin, Julia Etchin, Lee Lawton, Stephen E Sallan, Lewis B Silverman,[...]. Science 2014
448
12

The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity.
Simak Ali, Dean A Heathcote, Sebastian H B Kroll, Ashutosh S Jogalekar, Bodo Scheiper, Hetal Patel, Jan Brackow, Alekasandra Siwicka, Matthew J Fuchter, Manikandan Periyasamy,[...]. Cancer Res 2009
99
12

Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Bjoern Chapuy, Michael R McKeown, Charles Y Lin, Stefano Monti, Margaretha G M Roemer, Jun Qi, Peter B Rahl, Heather H Sun, Kelly T Yeda, John G Doench,[...]. Cancer Cell 2013
484
12

Coactivator condensation at super-enhancers links phase separation and gene control.
Benjamin R Sabari, Alessandra Dall'Agnese, Ann Boija, Isaac A Klein, Eliot L Coffey, Krishna Shrinivas, Brian J Abraham, Nancy M Hannett, Alicia V Zamudio, John C Manteiga,[...]. Science 2018
881
12

THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors.
Florencia Cayrol, Pannee Praditsuktavorn, Tharu M Fernando, Nicholas Kwiatkowski, Rosella Marullo, M Nieves Calvo-Vidal, Jude Phillip, Benet Pera, Shao Ning Yang, Kaipol Takpradit,[...]. Nat Commun 2017
62
19


Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers.
Denes Hnisz, Jurian Schuijers, Charles Y Lin, Abraham S Weintraub, Brian J Abraham, Tong Ihn Lee, James E Bradner, Richard A Young. Mol Cell 2015
263
12

Mediator kinase inhibition further activates super-enhancer-associated genes in AML.
Henry E Pelish, Brian B Liau, Ioana I Nitulescu, Anupong Tangpeerachaikul, Zachary C Poss, Diogo H Da Silva, Brittany T Caruso, Alexander Arefolov, Olugbeminiyi Fadeyi, Amanda L Christie,[...]. Nature 2015
221
12

Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer.
Victor Quereda, Simon Bayle, Francesca Vena, Sylvia M Frydman, Andrii Monastyrskyi, William R Roush, Derek R Duckett. Cancer Cell 2019
90
13

TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II.
Kira Glover-Cutter, Stéphane Larochelle, Benjamin Erickson, Chao Zhang, Kevan Shokat, Robert P Fisher, David L Bentley. Mol Cell Biol 2009
215
11


Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Mei Zeng, Nicholas P Kwiatkowski, Tinghu Zhang, Behnam Nabet, Mousheng Xu, Yanke Liang, Chunshan Quan, Jinhua Wang, Mingfeng Hao, Sangeetha Palakurthi,[...]. Elife 2018
68
16

Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion.
Miguel Ganuza, Cristina Sáiz-Ladera, Marta Cañamero, Gonzalo Gómez, Ralph Schneider, María A Blasco, David Pisano, Jesús M Paramio, David Santamaría, Mariano Barbacid. EMBO J 2012
64
17

Transcription Factors Activate Genes through the Phase-Separation Capacity of Their Activation Domains.
Ann Boija, Isaac A Klein, Benjamin R Sabari, Alessandra Dall'Agnese, Eliot L Coffey, Alicia V Zamudio, Charles H Li, Krishna Shrinivas, John C Manteiga, Nancy M Hannett,[...]. Cell 2018
588
11

CDK7 inhibitors as anticancer drugs.
Georgina P Sava, Hailing Fan, R Charles Coombes, Lakjaya Buluwela, Simak Ali. Cancer Metastasis Rev 2020
39
28

Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.
Maria Rusan, Kapsok Li, Yvonne Li, Camilla L Christensen, Brian J Abraham, Nicholas Kwiatkowski, Kevin A Buczkowski, Bruno Bockorny, Ting Chen, Shuai Li,[...]. Cancer Discov 2018
61
16

TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II.
Md Sohail Akhtar, Martin Heidemann, Joshua R Tietjen, David W Zhang, Rob D Chapman, Dirk Eick, Aseem Z Ansari. Mol Cell 2009
207
10

Transcriptional amplification in tumor cells with elevated c-Myc.
Charles Y Lin, Jakob Lovén, Peter B Rahl, Ronald M Paranal, Christopher B Burge, James E Bradner, Tong Ihn Lee, Richard A Young. Cell 2012
964
10

Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Steven R Whittaker, Aurélie Mallinger, Paul Workman, Paul A Clarke. Pharmacol Ther 2017
183
10

The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells In Vitro and In Vivo.
Yu Zhang, Liang Zhou, Dipankar Bandyopadhyay, Kanika Sharma, Alexander Joseph Allen, Maciej Kmieciak, Steven Grant. Clin Cancer Res 2019
27
37

Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
Bowen Sun, Seth Mason, Robert C Wilson, Starr E Hazard, Yubao Wang, Rong Fang, Qiwei Wang, Elizabeth S Yeh, Meixiang Yang, Thomas M Roberts,[...]. Oncogene 2020
23
43

THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism.
Zhu-Jun Cheng, Du-Ling Miao, Qiu-Yun Su, Xiao-Li Tang, Xiao-Lei Wang, Li-Bin Deng, Hui-Dong Shi, Hong-Bo Xin. Acta Pharmacol Sin 2019
26
34

Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
Liqiang Zhong, Sihao Yang, Yuming Jia, Kaijian Lei. J Cell Biochem 2018
15
60

Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Shaokun Shu, Charles Y Lin, Housheng Hansen He, Robert M Witwicki, Doris P Tabassum, Justin M Roberts, Michalina Janiszewska, Sung Jin Huh, Yi Liang, Jeremy Ryan,[...]. Nature 2016
356
9

Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.
Calla M Olson, Baishan Jiang, Michael A Erb, Yanke Liang, Zainab M Doctor, Zinan Zhang, Tinghu Zhang, Nicholas Kwiatkowski, Myriam Boukhali, Jennifer L Green,[...]. Nat Chem Biol 2018
231
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.